News Releases
- December 7, 2020Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
- December 3, 2020Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference
- November 16, 2020Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
- November 12, 2020Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
- November 2, 2020Annovis Bio CEO to Present at Meridian Clinical Trials Summit
- October 29, 2020Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay
- October 22, 2020Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award
- October 20, 2020Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair
- October 15, 2020Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
- October 12, 2020Annovis Bio to Present at the 2020 BIO Investor Forum
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
25
Notification filed by a National Securities Exchange to Report the Removal from listing and registration of matured , redeemed or retired securities
Nov 26, 2021
E-mail Alerts
Back to Top